EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Sustained MRD‐Negative Complete Remission of T‐PLL With CNS Involvement Following Treatment With Systemic and Intrathecal Alemtuzumab

Isobel Rowe, Anthony D. Jeffrey, Ariana McCauley, Linda Lee, Arda Leyton, Khilna Kunverji, Poomahal Kumar, Matthew Greenwood

eJHaem · 2026-12 · 7 (6)

DOI: 10.1002/jha2.70456 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Background T‐cell prolymphocytic leukaemia (T‐PLL) with central nervous system (CNS) involvement is uncommon and evidence guiding its treatment is limited. Case summary We describe the successful treatment of T‐PLL with leptomeningeal involvement using intrathecal alemtuzumab followed by allogeneic haematopoietic stem cell transplantation. Residual disease monitoring of T‐cell receptor clonotypes by next‐generation sequencing was performed to assess treatment response and guide post‐SCT intervention. At 24 months post‐SCT, the patient remains in sustained molecular remission. Conclusion This case adds to the limited literature supporting activity of intrathecal alemtuzumab in refractory CNS disease and highlights the utility of molecular monitoring following SCT. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →